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Abstract
Coronary artery bypass surgery for coronary artery thrombosis in patients with polycythaemia rubra
vera has been rarely described. The main issue with such patients is their risk of both bleeding and
thrombosis and as such the ideal postoperative management of such cases is unknown. Hereby, we
describe a case of a 62-year-old man with polycythaemia rubra vera who underwent coronary artery
bypass surgery. Although his initial postoperative course was complicated, his long-term outcome
was good.
Introduction
Polycythaemia rubra vera is a chronic myeloproliferative
disorder that is characterized by excessive red blood cell
production and unlike other forms of polycythaemia, it
can cause both bleeding and thrombosis in the same
patient. Only few cases have been reported in the literature
where coronary artery bypass was performed successfully
in such cases. The ideal postoperative management is
currently unknown.
Case presentation
A 62-year-old Middle Eastern man was admitted electively
for coronary artery bypass graft (CABG) for ischemic heart
disease and ongoing angina (Canadian cardiovascular
society class III symptom) despite maximal medical
therapy. His past history included non-insulin dependent
diabetes mellitus, chronic obstructive pulmonary disease,
hypertension and hyperlipidaemia. He was also suffering
from polycythaemia Rubra Vera (PRV) for the previous
2 years and was on medical therapy (Hydroxyurea) and
regular venesection. He was a former smoker and had no
family history of ischemic heart disease. He works as a civil
servant. His weight was 90 kg and his height was 174 cm.
Coronary angiography showed occluded right coronary
artery, 60% proximal stenosis in left anterior descending
artery (LAD) and 80% stenosis in 1st obtuse marginalis
(OM1). His ejection fraction was 50%. Physical exami-
nation at the time of admission was unremarkable. His
preoperative bloods showed normal levels of haemo-
globin, red blood cells, white blood cells and platelet
count. His renal and liver functions were normal with an
unremarkable chest radiograph appearance. He under-
went CABG *4 with the aid of cardiopulmonary bypass
(CPB) where left internal thoracic artery was anastomosed
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OM1, ramus intermidius, and posterior diagonal artery
(PDA). Myocardial protection was achieved using ante-
grade and retrograde cold blood cardioplegia. CPB time
was 130 minutes and aortic cross clamp time was
78 minutes. All flows through new grafts were measured
using intraoperative flow doppler and were satisfactory.
Patient was then extubated 4 hours later and required no
inotropic support. Aspirin, persantin and low-molecular
weight heparin were started in the first postoperative day.
He remained in a stable condition until his 4th post-
operative day when he started spiking fevers and devel-
oped left sided pleural effusion. His renal function
remained normal but his white blood cell count increased
to 20 × 109/L (normal range 4.2-9.1 × 109 /L) with an
increased platelet count to 605 × 109/L (normal range
140-400 × 109/L). His red blood cells dropped to
3×1 0 1 2 / L( n o r m a lr a n g e4 . 6 - 6 . 1×1 0 1 2/ L )a n d
haematocrit was low 0.29 L/L (normal range 0.4-0.5 L/L).
His hydroxyurea medication was recommended at that
stage following review by hematologist. Subsequently,
the patient started to deteriorate with creatinine
levels increasing to 270 micromol/L (normal range
80-115 Micro mol/L) and platelet count rising to
1369 × 109 /L and later became undetectable by machine.
His pleural effusion got worse and pleural tapping was
carried out yielding 750 ml of hemorrhagic effusion which
later showed no bacterial growth. Ultrasound of kidneys
was normal. A second pleural tapping was also required
4 days later yielding 300 ml of hemorrhagic effusion. The
dose of hydroxyurea was then increased and the patient
responded well to this. He made a slow but sustainable
recovery and was discharged home on the 15th post-
operative day. On follow-up in our clinic, both his kidney
function and platelet counts returned to normal.
Discussion
Polycythaemia rubra vera (PRV) is a chronic myeloproli-
ferative disease characterized by excessive red blood cell
production and in 50% of patients proliferation of all cell
lines (i.e. thrombocytosis and leucocytosis). It is more
common in men [1] with a prevalence of 4-16 per million
[2]. PRV can cause both bleeding and thrombosis in the
same patient [3]. Quantitative platelet derangement plays
a role in the development of thrombosis and ischemia
which leads to increased incidence of stroke, myocardial
infarction and arterial or venous thrombosis [4]. Platelet
abnormalities may also predispose patients to bleeding at
virtually any site [2]. Myocardial infarction and sudden
death are complications of newly diagnosed and untreated
PRV, most often in the people >65 years old with
underlying coronary artery disease [2].
The accepted treatment for acute myocardial infarction in
patients with PRV is based on exchange phlebotomy and
platelet pharesis [2]. Routine therapy such as aspirin,
heparin, low molecular weight heparin and thrombolysis
is still not clear [2]. Some authors have reported the use of
oralanticoagulantswithaspirinandclopidegrolasameans
to prevent thrombosis in such patients [5]. Acceleration of
atherosclerosisandthrombosishasbeenshowntooccuras
a complication of PRV [1]. Coronary artery bypass graft
(CABG) surgery, in turn, has been performed very rarely in
the setting of PRV [5-7]. One interesting finding in these
reported cases is that the long term outcome for such
patients is good in terms of clinical outcome and
angiographic patency of the coronary grafts. Our case
remained well 2 years later with no recurrence of angina.
The main perioperative concern with patients with PRV
undergoing CABG is twofold. The first is the increased risk
of graft thrombosis compared to normal population due
to hyperviscosity [8] and the second is their increased risk
of bleeding following cardiopulmonary bypass. The
management of the increased thrombosis risk depends
on adequate anticoagulation in such patients including
a combination of antiplatelet agents (e.g. aspirin and
clopidegrol) with addition of anticoagulants [5,8], either
orally (such as warfarin) or subcutaneously/intravenously
(such as low molecular weight heparin/unfractionated
heparin). Such management remains largely unknown,
however, few reported cases have shown the success of
such combination therapy [5]. The second main problem
of bleeding tendency requires a dual control of poly-
cythaemia disease process (through the use of cytoreduc-
tive therapy or exchange phlebotomy) and the adequate
control of any coagulation derangements. Various
polycythaemia medications have been used in varying
time postoperatively following CABG (including hydro-
xyurea [5] and 32 P [7]. However, the exact timing of
instituting these therapies in the postoperative course is
unknown but assumed to be better in the immediate
postoperative period [5,7].
The spectrum of complications observed in our patient
(i.e. hemorrhagic pleural effusion, acute renal failure with
reactive thrombocytosis) responded well to increased dose
of cytoreductive therapy (hydroxyurea) and combination
of antiplatelet agents (aspirin and persantin) with low
molecular weight heparin. We did not have to resort to
oral anticoagulation partly because of the increased risk of
bleeding in a PRV patient who has already developed
hemorrhagic effusion. Although we started hydroxyurea
medication to our patient on the 4th postoperative day
(based on recommendation by a haematologist), we
believe that earlier commencement of such medication
might have prevented some of the observed complication
in our patient. We believe that cases such as ours should
have hydroxyurea commenced on day one and escalated
in dosage according to clinical outcome.
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Patients with PRV undergoing CABG may have an
increased risk of bleeding and the development of pleural
effusion. There may be a risk of developing renal
dysfunction due to thrombocythaemia. Proper manage-
ment and monitoring of these patients in a multi-
disciplinary fashion may reduce these complications,
Abbreviations
CABG, coronary artery bypass graft; CPB, cardiopulmon-
ary bypass; LAD, left anterior descending artery; OM1,
1
st obtuse marginalis artery; PDA, posterior diagonal
artery; PRV, polycythaemia rubra vera.
Consent
Written informed consent was obtained from the patient
for publication of this case report and accompanying
images. A copy of the written consent is available for
review by the Editor-in-Chief of this journal.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
JAF wrote the initial manuscript. FAS and NAS were major
contributors in the writing of the manuscript. NAS and
AAD conducted the literature review in this paper and
edited the paper. All authors read and approved the final
manuscript.
References
1. Tefferi A, Solberg LA, Silverstein MN: A clinical updates in
polycythaemia vera and essential thrombocythaemia. Am J
Med 2000, 109:141-149.
2. Venegoni O, Cyprus G: Polycythaemia and the heart: a review.
Tex Heart Inst J 1994, 21:198-201.
3. Raundi ML, Stocco F, Rossi C, Tison T, Girolami A: Thrombosis and
hemorrhage in thrombocytosis: evaluation of large cohort of
patients (357 cases). J Med 1991, 22:213-223.
4. Schwarcz TH, Hogan LA, Endean ED, Roitman IT, Kazmers A,
Hyde GL: Thromboembolic complication of polycythaemia:
polycythaemia vera versus smokers’ polycythaemia. J Vasc Surg
1993, 17:518-523.
5. Oz BS, Asgun F, Akay HT, Kaya E, Kuralay E, Tatar H: Anti-
coagulation after coronary artery bypass surgery in patients
with polycythaemia vera: report of two cases. J Card Surg 2007,
22:420-422.
6. Arora D, Juneja R, Pendarkar D, Metha Y, Trehan N: Off-pump
coronary artery bypass grafting in a polycythaemic patient-
case report and review of the literature. Ann Card Anaesth 2007,
10:54-57.
7. Gosalakkal JA, Neligan MC: Coronary artery bypass grafting for
coronary thrombosis complicating polycythaemia rubra
vera: case report. Scand J Thorac Cardiovasc Surg 1991, 25:159-160.
8. Ural AU, Cetin T, Avcu F: Antithrombotic challenges after
coronary artery surgery in patients with polycytemia vera.
J Card Surg 2008, 23:410.
Do you have a case to share?
Submit your case report today
￿ Rapid peer review
￿ Fast publication
￿ PubMed indexing
￿ Inclusion in Cases Database
Any patient, any case, can teach us
something
www.casesnetwork.com
Page 3 of 3
(page number not for citation purposes)
Cases Journal 2009, 2:8126 http://casesjournal.com/casesjournal/article/view/8126